(Q36324199)

13 August 2017

1 reference

title

Treatment of pituitary tumors: pegvisomant (English)

1 reference

13 August 2017

Angela N Paisley

1

1 reference

13 August 2017

William M Drake

series ordinal

2

1 reference

13 August 2017

publication date

1 October 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

28

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

111-114

1 reference

Growth hormone receptor antagonist improves insulin resistance in acromegaly

13 August 2017

cites work

1 reference

12 December 2020

Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.

1 reference

12 December 2020

The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.

1 reference

12 December 2020

Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly

1 reference

12 December 2020

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

1 reference

12 December 2020

Pegylated interferon vs standard interferon for chronic hepatitis C

1 reference

12 December 2020

Outcome of surgery for acromegaly--the experience of a dedicated pituitary surgeon

1 reference

12 December 2020

Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly

1 reference

12 December 2020

Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action.

1 reference

12 December 2020

Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly

1 reference

12 December 2020

The effect of growth hormone replacement on cortisol metabolism and glucocorticoid sensitivity in hypopituitary adults.

1 reference

12 December 2020

Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly

1 reference

12 December 2020

Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly.

1 reference

12 December 2020

Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant

1 reference

12 December 2020

Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly

1 reference

12 December 2020

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

1 reference

12 December 2020

Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly

1 reference

12 December 2020

Cabergoline in the treatment of acromegaly: a study in 64 patients.

1 reference

12 December 2020

Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size

1 reference

12 December 2020

1 reference

12 December 2020

Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure.

1 reference

12 December 2020

Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group

1 reference

12 December 2020

Identifiers

DOI

10.1385/ENDO:28:1:111

1 reference

Dimensions Publication ID

13 August 2017

1042721392

0 references

1 reference